Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 15, Issue 12
|
pp. 5650–5661
Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma
Back to article
Figure 8
(8 of 8)
−
100%
+
Figure 8.
Validation of the immune prognostic model (IPM) in clinical tissue samples by performing qRT-PCR assay in lung adenocarcinoma (LUAD) mucin 16 (MUC16) mutation tissue samples and LUAD non-MUC16 mutation tissue samples.
